Cresco Labs (CRLBF) Other Non-Current Assets (2019 - 2026)
Cresco Labs (CRLBF) posted Other Non-Current Assets of $13.9 million for Q1 2026, down 1.58% on a QoQ basis from $14.1 million in Q4 2025, and down 17.91% year-over-year from $16.9 million in Q1 2025.
Cresco Labs (CRLBF) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Cresco Labs' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- Quarterly Other Non-Current Assets fell 17.91% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 17.91% YoY) and the FY2025 annual result came in at $14.1 million, down 5.94% from the prior year.
- Other Non-Current Assets was $13.9 million for Q1 2026 at Cresco Labs, down from $14.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $22.9 million in Q3 2025 and bottomed at $4.2 million in Q1 2022.
- A 5-year average of $10.5 million and a median of $9.4 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets plunged 36.64% — and 2025, when it surged 212.4%.
- Cresco Labs' Other Non-Current Assets stood at $9.4 million in 2022, then plunged by 36.64% to $6.0 million in 2023, then jumped by 150.67% to $15.0 million in 2024, then decreased by 5.94% to $14.1 million in 2025, then retreated by 1.58% to $13.9 million in 2026.
- Business Quant data shows CRLBF's Other Non-Current Assets at $13.9 million in Q1 2026, $14.1 million in Q4 2025, and $22.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 13.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.88 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 22.90 Mn |
| Jun 30, 2025 | 13.90 Mn |
| Mar 31, 2025 | 16.90 Mn |
| Dec 31, 2024 | 14.99 Mn |
| Sep 30, 2024 | 7.33 Mn |
| Jun 30, 2024 | 7.57 Mn |
| Mar 31, 2024 | 7.71 Mn |
| Dec 31, 2023 | 5.98 Mn |
| Jun 30, 2023 | 4.98 Mn |
| Mar 31, 2023 | 9.92 Mn |
| Dec 31, 2022 | 9.44 Mn |
| Jun 30, 2022 | 4.22 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 4.21 Mn |
| Sep 30, 2021 | 4.14 Mn |
| Mar 31, 2021 | 3.91 Mn |
| Dec 31, 2020 | 3.71 Mn |
| Dec 31, 2019 | 62.11 Mn |